Hostname: page-component-76d6cb85b7-dqfph Total loading time: 0 Render date: 2026-07-15T04:18:35.180Z Has data issue: false hasContentIssue false

The Evidence for the Pharmaceutical Strengthening of Attachment: What, Precisely, Would Love Drugs Enhance?

Published online by Cambridge University Press:  18 November 2022

Peter N. Herissone-Kelly*
Affiliation:
School of Humanities, Language and Global Studies, University of Central Lancashire, Preston PR1 2HE, UK
*
Corresponding author. Email: pnherissone-kelly@uclan.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

In recent decades, scientists have begun to identify the brain processes and neurochemicals associated with the different stages of love, including the all-important stage of attachment. Experimental findings—readily seized upon by those bioethicists who want to urge that we sometimes have good reason pharmaceutically to enhance flagging relationships—are presented as demonstrating that attachment is regulated and strengthened by the neuropeptides oxytocin and vasopressin. I shall argue, however, that often what the experimental data in fact show is only that exogenous administration of such chemicals can control and intensify the trappings of attachment, not attachment itself. That this is sometimes overlooked by both scientists and ethicists, is due to attachment being miscategorised as a set of feelings or a drive, rather than as a disposition to think about, feel toward, and behave toward its object in certain distinctive ways.

Information

Type
Research Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press